retatrutide type 2 diabetes phase 2 trial hba1c Medscape | The investigational triple GLP-1/GIP/glucagon receptor agonist produced significant weight loss and A1c reduction in people Retatrutide Before and After: Doctor

Siegel et al

Quality Weight Loss Care, Made Simple Thoughtful, clinician-guided weight management designed to fit your life

Alberto Ortiz made substantial contributions in the design of the work, bibliographic search, drafted the manuscript, reviewed the manuscript, interpretation, discussion and conclusions, provided intellectual senior input, contribute to text and contents of the manuscript including revisions and edits and approve of the content of the manuscript and agree to be held accountable for the work

More reported that they had stopped taking the drugs due to difficulty affording them (14%) than reported they had stopped due to side effects (13%)